2021 ABPI CODE OF PRACTICE FOR THE PHARMACEUTICAL

Transcript:2021 ABPI CODE OF PRACTICE FOR THE PHARMACEUTICAL:
2021 ABPI CODE OF PRACTICE FOR THE PHARMACEUTICAL INDUSTRY Please refer to the Code for the supplementary information Overarching Requirements Clauses 1-10 (Grey Section) Clause 1 Scope of the Code and Definition of Certain Terms 1.1 This Code applies to the promotion of medicines to members of the United Kingdom (UK) health professions and to other relevant decision makers. For the purposes of the application of the Code, the UK includes the Channel Islands and the Isle of Man. The Code also applies to a number of areas which are non-promotional, including information made available to the public about prescription only medicines. It does not apply to the promotion of over-the-counter (OTC) medicines to members of the health professions when the object of that promotion is to encourage their purchase by members of the public. 1.2 Information or promotional material about medicines which is placed on the internet outside the UK will be regarded as coming within the scope of the Code, if it was placed there by: a UK company/with a UK company’s authority, or an affiliate of a UK company, or with the authority of such a company, and it makes specific reference to the availability or use of the medicine in the UK. Clause 1 Scope of the Code and Definition of Certain Terms 1.3 ‘Collaborative Working’ refers to pharmaceutical companies working with other organisations to deliver initiatives which either enhance patient care or are for the benefit of patients or alternatively benefit the National Health Service (NHS) and, as a minimum, maintain patient care. Further details are given in Clause 20. 1.4 ‘Contribution to costs related to events’ in relation to the disclosure of transfers of value means providing or covering the costs of travel, accommodation and/or registration fees to support the attendance of an individual to an event organised or created by a company and/or independent organisation. When providing sponsorship of events/meetings to organisations, associations etc such contributions may include costs for subsistence (food and drink). 1.5 ‘Donations and grants’ collectively mean providing funds, benefits-in-kind or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to the benefit of the pharmaceutical company in return. Donations and grants to individuals are prohibited. In general, donations are physical items, services or benefits-in-kind which may be offered